NCT03863977

Brief Summary

To compare the postoperative analgesic effect of two doses of dexamethasone added to bupivacaine in ultrasound-guided TAP block for inguinal hernia repair.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Mar 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 5, 2019

Completed
10 days until next milestone

Study Start

First participant enrolled

March 15, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

April 28, 2020

Status Verified

April 1, 2020

Enrollment Period

9 months

First QC Date

March 3, 2019

Last Update Submit

April 27, 2020

Conditions

Keywords

TAP blockinguinal hernia

Outcome Measures

Primary Outcomes (1)

  • time of the first analgesic request

    time of the first analgesic request in the first postoperative 24 hours ,patients will receive analgesia if visual analog scale (VAS) score more than 3

    in the first postoperative 24 hours

Secondary Outcomes (1)

  • change in visual analog scale (VAS)

    2nd, 4th, 8th, 16th, and 24th postoperative hours.

Study Arms (3)

Dex4 group

ACTIVE COMPARATOR

After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.

Drug: DexamethasoneDrug: Bupivacaine

Dex8 group

ACTIVE COMPARATOR

After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.

Drug: DexamethasoneDrug: Bupivacaine

control group

ACTIVE COMPARATOR

After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.

Drug: Bupivacaine

Interventions

After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.

Also known as: dexamethasone acetate
Dex4 groupDex8 group

After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.

Also known as: plain marcaine
Dex4 groupDex8 groupcontrol group

Eligibility Criteria

Age18 Years - 60 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients' age from 18 to 60 years old,
  • physical status ASA I-II (by the American Society of Anesthesiologists),
  • Elective unilateral open inguinal hernia repair,
  • Under spinal anesthesia

You may not qualify if:

  • age \< 18 or \> 60,
  • American society of anesthesiologist (ASA)class III-IV,
  • known allergy to amino amide local anesthetics,
  • skin infection and diseases at site of injection.
  • coagulation disorders,
  • patients with body mass index (BMI) \> 35 kg/m2,
  • scrotal hernias,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university hospitals

Asyut, Assiut Governorate, Egypt, 715715, Egypt

Location

MeSH Terms

Conditions

Hernia, Inguinal

Interventions

Dexamethasonedexamethasone acetateBupivacaine

Condition Hierarchy (Ancestors)

Hernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Amany Hassan, Lectural

    Assiut university, Egypt

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
A blinded physician prepared the study medications in color coded syringes.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: 60 patients will be divided into two groups according to the dose of dexamethasone added to bupivacaine in the TAP block, I - group ( Group D4 ) 4mg of dexamethasone will be added II - group ( Group D8 ) 8mg of dexamethasone will be added. III-group(control) bupivacaine alone
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 3, 2019

First Posted

March 5, 2019

Study Start

March 15, 2019

Primary Completion

December 1, 2019

Study Completion

January 1, 2020

Last Updated

April 28, 2020

Record last verified: 2020-04

Locations